EH301 for the Treatment of ALS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03489200 |
Recruitment Status :
Completed
First Posted : April 5, 2018
Last Update Posted : May 18, 2018
|
Sponsor:
Elysium Health
Collaborators:
Fundación Universidad Católica de Valencia San Vicente Mártir
University of Valencia
Information provided by (Responsible Party):
Elysium Health
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | March 27, 2018 | ||||
First Posted Date ICMJE | April 5, 2018 | ||||
Last Update Posted Date | May 18, 2018 | ||||
Actual Study Start Date ICMJE | January 2017 | ||||
Actual Primary Completion Date | June 2017 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
ALSFRS-r [ Time Frame: 6 months ] ALS Functional Rating Scale - revised score is a summation of ratings across across fine and gross motor, bulbar and respiratory functional domains. The scale ranges from 0-48, with higher total score representing better outcomes. The twelve subscales are rated on a five-point scale from 0 (can't do) to 4 (normal ability) and combined to compute the total score. This outcome measures change observed from baseline to 6 months.
|
||||
Original Primary Outcome Measures ICMJE |
|
||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | EH301 for the Treatment of ALS | ||||
Official Title ICMJE | EH301 for the Treatment of Amyotrophic Lateral Sclerosis: a Placebo-Controlled Study | ||||
Brief Summary | The objective of this trial is to evaluate the efficacy and tolerability of EH301 in patients with amyotrophic lateral sclerosis. Patients with ALS are randomized to receive either EH301 or placebo daily and undergo active evaluation for 6 months. | ||||
Detailed Description | Not Provided | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Not Applicable | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Outcomes Assessor) Primary Purpose: Treatment |
||||
Condition ICMJE | Amyotrophic Lateral Sclerosis | ||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Actual Enrollment ICMJE |
32 | ||||
Original Actual Enrollment ICMJE | Same as current | ||||
Actual Study Completion Date ICMJE | June 2017 | ||||
Actual Primary Completion Date | June 2017 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Spain | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03489200 | ||||
Other Study ID Numbers ICMJE | H1479983999044 | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | Elysium Health | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Elysium Health | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE |
|
||||
Investigators ICMJE | Not Provided | ||||
PRS Account | Elysium Health | ||||
Verification Date | May 2018 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |